Similarly, two enzymes catalyzing rate limiting steps upstream of FASN in de novo fatty acid synthesis, ACC and ACLY, are often dysregulated in cancer and have been proposed as breast cancer therapeutic targets [52–54]. This evidence concerns the gene ACLY and breast cancer.